Research programme: insulin-like growth factor therapeutics - Insmed

Drug Profile

Research programme: insulin-like growth factor therapeutics - Insmed

Alternative Names: rhIGBP-3 - Insmed

Latest Information Update: 13 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Insmed
  • Class Recombinant proteins
  • Mechanism of Action Insulin like growth factor binding protein 3 modulators; Insulin-like growth factor I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 13 Apr 2012 Research programme: insulin-like growth factor therapeutics - Insmed is available for licensing as of 13 Mar 2012. http://www.insmed.com/
  • 21 Mar 2005 Preclinical trials in Prostate cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top